Recurrence and Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Synchronous and Metachronous Peritoneal Metastases of Colorectal Origin
Cancers · 01.02.2024 · 16 (3) · 631
DOI: 10.3390/cancers16030631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 01.02.2024. Verfasst von Mette Fugleberg Nielsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Aarhus University Hospital, 8200 Aarhus N, Denmark. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has improved the 5-year survival for colorectal cancer (CRC) patients with peritoneal metastases (PM). Little is known about recurrence patterns and recurrence rates between synchronous (S) and metachronous (M) PM following CRS+HIPEC. We aimed to describe the recurrence patterns, overall survival (OS) and disease-free survival (DFS) in S-PM and M-PM patients after complete CRS+HIPEC. From June 2006 to December 2020, a prospective cohort study included 310 CRC patients, where 181 patients had S-PM (58.4%) and 129 patients had M-PM (41.6%). After a median 10.3-month follow-up, 247/310 (79.7%) patients experienced recurrence, and recurrence sites included isolated peritoneal (32.4%), multifocal (peritoneal and liver and/or lung(s)) (22.7%), isolated liver (17.8%), isolated lung (10.5%) and other (16.6%) sites. Recurrence patterns did not differ between S-PM and M-PM. M-PM patients had an impaired DFS compared to S-PM patients (9.4 months (95% CI: 7.3–12.1) vs. 12.5 months (95% CI: 11.2–13.9), p = 0.01). The median OS was similar for S-PM and M-PM (38.4 months (95% CI: 31.2–46.8) vs. 40.8 months (95% CI: 28.8–46.8), p = 0.86). Despite frequent recurrence at extraperitoneal locations, long-term survival was achievable after CRS+HIPEC in CRC patients with PM. The recurrence patterns and OS did not differ between groups, yet M-PM patients had a shorter DFS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Aarhus University Hospital, 8200 Aarhus N, Denmark.
- Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark.
ORCID-Profile: Mette Fugleberg Nielsen, Jonas Amstrup Funder, Lene Hjerrild Iversen
Zitieren
APA
Nielsen, M. F., Ravn, S., Sørensen, M. M., Funder, J. A., & Iversen, L. H. (2024). Recurrence and Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Synchronous and Metachronous Peritoneal Metastases of Colorectal Origin. Cancers, 16(3), 631. https://doi.org/10.3390/cancers16030631
Vancouver
Nielsen MF, Ravn S, Sørensen MM, Funder JA, Iversen LH. Recurrence and Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Synchronous and Metachronous Peritoneal Metastases of Colorectal Origin. Cancers. 2024;16(3):631. doi:10.3390/cancers16030631
BibTeX
@article{Nielsen2024,
author = {Nielsen, Mette Fugleberg and Ravn, Sissel and Sørensen, Mette Møller and Funder, Jonas Amstrup and Iversen, Lene Hjerrild},
title = {Recurrence and Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Synchronous and Metachronous Peritoneal Metastases of Colorectal Origin},
journal = {Cancers},
year = {2024},
volume = {16},
number = {3},
pages = {631},
doi = {10.3390/cancers16030631}
}
EUVIMED